Teva Pharmaceutical Industries (TEVA) Rating Increased to Buy at Citigroup

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by equities researchers at Citigroup from a “neutral” rating to a “buy” rating in a research note issued on Thursday. The brokerage presently has a $24.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 24.87% from the company’s current price.

TEVA has been the subject of a number of other research reports. BTIG Research increased their price objective on Teva Pharmaceutical Industries to $20.00 in a research note on Friday, December 15th. Gabelli reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 13th. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Evercore ISI set a $38.00 price objective on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, Goldman Sachs Group raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Friday, December 15th. Seven equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $21.16.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $19.22 on Thursday. The stock has a market capitalization of $19,030.00, a P/E ratio of -3.27 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.15.

Several institutional investors have recently made changes to their positions in the stock. Fieldpoint Private Securities LLC bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $171,000. Arthur Zaske & Associates LLC bought a new position in Teva Pharmaceutical Industries in the third quarter worth $372,000. Sterling Capital Management LLC bought a new position in Teva Pharmaceutical Industries in the third quarter worth $263,000. Point72 Asset Management L.P. bought a new position in Teva Pharmaceutical Industries in the third quarter worth $2,200,000. Finally, Chevy Chase Trust Holdings Inc. raised its holdings in Teva Pharmaceutical Industries by 81.5% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock worth $215,000 after purchasing an additional 5,497 shares in the last quarter. Institutional investors own 51.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://transcriptdaily.com/2018/01/06/teva-pharmaceutical-industries-teva-rating-increased-to-buy-at-citigroup.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply